Yang Jing, Dong Meilian, Shui Yifang, Zhang Yue, Zhang Zhigang, Mi Yin, Zuo Xiaoxiao, Jiang Li, Liu Ke, Liu Zheyan, Gu Xiaobin, Shi Yonggang
1Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000 Henan People's Republic of China.
2Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000 Henan People's Republic of China.
Cancer Cell Int. 2020 Mar 30;20:96. doi: 10.1186/s12935-020-01187-x. eCollection 2020.
Programmed death-ligand 1 (PD-L1) was the first identified ligand of programmed death-1 (PD-1). PD-1/PD-L1 interactions inhibit T cell-mediated immune responses, limit cytokine production, and promote tumor immune escape. Recently, many studies have investigated the prognostic value of PD-L1 expression in patients with melanoma. However, the results of these analyses remain a subject of debate. We have therefore carried out a meta-analysis to identify the prognostic role of PD-L1 in melanoma.
A thorough medical literature search was performed in the databases PubMed, Web of Science, and Embase until October 2019. The pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated to evaluate the correlation between PD-L1 overexpression and prognosis. Publication bias was evaluated using Begg's test and Egger's test.
Thirteen articles with 1062 enrolled patients were included in this meta-analysis. High PD-L1 expression did not correlate with overall survival (OS) (HR = 0.93, 95% CI 0.57-1.52, P = 0.781) or progression-free survival (PFS) (HR = 0.82, 95% CI 0.43-1.54, P = 0.535). However, PD-L1 overexpression correlated with the absence of lymph node (LN) metastasis (OR = 0.46, 95% CI 0.22-0.95, P = 0.036). Further, there was no significant relationship between PD-L1 expression and sex (OR = 1.29, 95% CI 0.90-1.84, P = 0.159), age (OR = 0.90, 95% CI 0.51-1.57, P = 0.708), or Eastern Cooperative Oncology Group Performance Status (OR = 0.55, 95% CI 0.06-4.83, P = 0.592).
This meta-analysis suggested that PD-L1 expression did not predict an inferior prognosis in patients with melanoma. However, high PD-L1 expression was associated with absence of LN metastasis in such patients.
程序性死亡配体1（PD-L1）是首个被鉴定出的程序性死亡1（PD-1）配体。PD-1/PD-L1相互作用可抑制T细胞介导的免疫反应，限制细胞因子产生，并促进肿瘤免疫逃逸。最近，许多研究探讨了PD-L1表达在黑色素瘤患者中的预后价值。然而，这些分析结果仍存在争议。因此，我们进行了一项荟萃分析，以确定PD-L1在黑色素瘤中的预后作用。
在PubMed、科学网和Embase数据库中进行全面的医学文献检索，截止至2019年10月。计算合并风险比（HR）和95%置信区间（95%CI），以评估PD-L1过表达与预后之间的相关性。使用Begg检验和Egger检验评估发表偏倚。
本荟萃分析纳入了13篇文章，共1062例患者。PD-L1高表达与总生存期（OS）（HR = 0.93，95%CI 0.57 - 1.52，P = 0.781）或无进展生存期（PFS）（HR = 0.82，95%CI 0.43 - 1.54，P = 0.535）均无相关性。然而，PD-L1过表达与无淋巴结（LN）转移相关（OR = 0.46，95%CI 0.22 - 0.95，P = 0.036）。此外，PD-L1表达与性别（OR = 1.29，95%CI 0.90 - 1.84，P = 0.159）、年龄（OR = 0.90，95%CI 0.51 - 1.57，P = 0.708）或东部肿瘤协作组体能状态（OR = 0.55，95%CI 0.06 - 4.83，P = 0.592）之间均无显著关系。
本荟萃分析表明，PD-L1表达并不能预测黑色素瘤患者的不良预后。然而，此类患者中PD-L1高表达与无LN转移相关。
